China Regenerative Medicine (08158) plans to strategically cooperate with China Star to acquire 55% of Kang Meizan's shares

Zhitong Finance App News, China Regenerative Medicine (08158) announced that on January 2, 2026, China Regeneration (Hong Kong) Investment Co., Ltd. (a wholly-owned subsidiary of the Company) and China Star Entertainment (BVI) Limited (China Star Group Co., Ltd., a wholly-owned subsidiary of China Star Group Limited, a company listed on the main board of the Hong Kong Stock Exchange Limited (stock code: 0326)) entered into a trading agreement, and China Regeneration (Hong Kong) agreed to do so at a cost HK$5,500 acquired 55% of the shares of Kangmeizan Biotechnology Development Co., Ltd. (formerly Hong Kong Dippenny Culture Media Co., Ltd.) (a wholly-owned subsidiary of China Star). After the acquisition is completed, China Regeneration (Hong Kong) and China Star will hold 55% and 45% of Kang Meizan's shares respectively. Transactions under the sales agreement are completed simultaneously.

In order to regulate the rights and obligations of China Regeneration (Hong Kong) and China Star as shareholders of Kangmeizan, China Star (Hong Kong), China Star and Kangmeizan entered into a shareholder agreement upon completion of the sale agreement.

It was further confirmed that Kangmeizan will invest in the Macau Special Administrative Region of the People's Republic of China as an investment holding company and operate the Macau clinic business in cooperation with other strategic investors.

This strategic cooperation will further utilize each party's respective expertise and resource advantages. On the one hand, the Group can use China Star's resources and business relationships in Macau to enhance the Group's business competitiveness in Macau; on the other hand, Kangmeizan can benefit from the Group's industry resources and rich experience in aesthetic medicine and aesthetic services and medical services to achieve synergy effects.

The strategic cooperation is an important milestone in the Group's expansion into new markets in Macau. All parties will not only achieve collaborative growth in their respective businesses through cooperation, but will also bring new market opportunities and commercial value to their respective companies.